iBio (IBIO) Projected to Post Quarterly Earnings on Friday

Key Points

• iBio is set to report Q3 2026 results before the market opens on May 1, with analysts forecasting ($0.06) EPS and $0.02 million in revenue, and an earnings call scheduled for May 14 at 4:00 PM ET.
• CFO Felipe Duran bought 24,835 shares at $2.02 on March 19, raising his stake by 222.96% to 35,974 shares; corporate insiders now own 2.75% of the stock.
• Shares opened at $1.81 (down 5.7%), trading in a 12‑month range of $0.56–$3.82 with a market cap of $65.4M, while analysts' consensus is an average Buy rating and a $4.75 price target.

iBio (NASDAQ:IBIO - Get Free Report) is expected to be announcing its Q3 2026 results before the market opens on Friday, May 1st. Analysts expect the company to announce earnings of ($0.06) per share and revenue of $0.02 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

iBio (NASDAQ:IBIO - Get Free Report) last released its quarterly earnings results on Tuesday, February 10th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.01). On average, analysts expect iBio to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

iBio Stock Down 5.7%

NASDAQ IBIO opened at $1.81 on Friday. iBio has a twelve month low of $0.56 and a twelve month high of $3.82. The company has a market capitalization of $65.41 million, a price-to-earnings ratio of -1.81 and a beta of 1.36. The company's 50 day moving average price is $2.26.

Insider Buying and Selling at iBio

In other iBio news, CFO Felipe Duran purchased 24,835 shares of the firm's stock in a transaction dated Thursday, March 19th. The stock was purchased at an average price of $2.02 per share, for a total transaction of $50,166.70. Following the completion of the purchase, the chief financial officer directly owned 35,974 shares of the company's stock, valued at $72,667.48. This trade represents a 222.96% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 2.75% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. XTX Topco Ltd purchased a new position in shares of iBio in the fourth quarter worth $71,000. Ikarian Capital LLC raised its stake in shares of iBio by 55.0% in the fourth quarter. Ikarian Capital LLC now owns 957,062 shares of the company's stock worth $1,847,000 after purchasing an additional 339,735 shares during the last quarter. Balyasny Asset Management L.P. raised its stake in shares of iBio by 10,440.2% in the fourth quarter. Balyasny Asset Management L.P. now owns 1,096,179 shares of the company's stock worth $2,116,000 after purchasing an additional 1,085,779 shares during the last quarter. Boothbay Fund Management LLC raised its stake in shares of iBio by 43.8% in the fourth quarter. Boothbay Fund Management LLC now owns 254,412 shares of the company's stock worth $491,000 after purchasing an additional 77,550 shares during the last quarter. Finally, Logos Global Management LP purchased a new position in shares of iBio in the fourth quarter worth $3,860,000. Hedge funds and other institutional investors own 7.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on IBIO shares. Chardan Capital restated a "buy" rating and set a $5.00 price target on shares of iBio in a research report on Thursday, April 9th. Weiss Ratings restated a "sell (d-)" rating on shares of iBio in a research report on Friday, March 27th. Wall Street Zen raised iBio from a "sell" rating to a "hold" rating in a report on Saturday, April 4th. Finally, JonesTrading began coverage on iBio in a report on Tuesday, March 3rd. They issued a "buy" rating and a $7.00 target price on the stock. Three research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $4.75.

About iBio

iBio, Inc, a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.